Attending ASCO 2026 reinforced one clear message: the future of oncology will depend not only on developing new therapies, but on understanding the biology that determines who benefits, who does not, and why resistance emerges.
For Nexomic, this is directly aligned with the work we are building. Cancer is heterogeneous, dynamic, and increasingly data-rich. To move precision oncology forward, molecular and clinical data must be transformed into decision-ready intelligence that can support drug development, patient stratification, resistance understanding, and better therapeutic strategies.
ASCO 2026 highlighted the growing importance of AI, biomarkers, multi-modal data, and translational science in shaping the next era of cancer care. At Nexomic, our mission is to help decode the hidden biology behind treatment response and resistance, turning complex multi-omics data into actionable insight for oncology research and development.